X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5184) 5184
Publication (292) 292
Newsletter (226) 226
Book Review (39) 39
Newspaper Article (30) 30
Book Chapter (25) 25
Conference Proceeding (16) 16
Magazine Article (16) 16
Book / eBook (11) 11
Dissertation (4) 4
Transcript (2) 2
Data Set (1) 1
Paper (1) 1
Reference (1) 1
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3505) 3505
immunotherapy (2547) 2547
bcg vaccine - therapeutic use (2019) 2019
male (1727) 1727
female (1686) 1686
bcg (1617) 1617
animals (1358) 1358
index medicus (1140) 1140
middle aged (1087) 1087
bcg vaccine - administration & dosage (1051) 1051
bladder cancer (1003) 1003
aged (1000) 1000
cancer (947) 947
urinary bladder neoplasms - therapy (935) 935
administration, intravesical (845) 845
urology & nephrology (842) 842
mice (799) 799
adult (772) 772
bcg vaccine (720) 720
bcg vaccine - adverse effects (685) 685
immunology (657) 657
urinary bladder neoplasms - drug therapy (599) 599
oncology (597) 597
urinary bladder neoplasms - pathology (557) 557
bacillus-calmette-guerin (551) 551
therapy (492) 492
care and treatment (489) 489
tuberculosis (486) 486
bcg vaccines (485) 485
carcinoma (399) 399
tumors (398) 398
research (397) 397
carcinoma, transitional cell - therapy (396) 396
adjuvants, immunologic - therapeutic use (378) 378
treatment outcome (378) 378
mycobacterium bovis - immunology (374) 374
melanoma - therapy (365) 365
prognosis (365) 365
time factors (360) 360
aged, 80 and over (350) 350
bcg vaccine - immunology (333) 333
immunotherapy - methods (330) 330
bacillus calmette-guerin (324) 324
follow-up studies (324) 324
health aspects (321) 321
vaccination (321) 321
urinary bladder neoplasms - immunology (307) 307
neoplasms - therapy (298) 298
combined modality therapy (291) 291
vaccines (287) 287
urology (283) 283
recurrence (280) 280
mycobacterium bovis (265) 265
bcg immunotherapy (262) 262
chemotherapy (260) 260
clinical trials as topic (260) 260
antineoplastic agents - therapeutic use (259) 259
neoplasm staging (258) 258
transitional-cell carcinoma (248) 248
adjuvants, immunologic - administration & dosage (244) 244
immunity, cellular (243) 243
infection (240) 240
antigens (226) 226
drug therapy, combination (226) 226
progression (225) 225
analysis (223) 223
bladder (222) 222
immunization (222) 222
risk factors (220) 220
carcinoma, transitional cell - pathology (217) 217
adolescent (212) 212
neoplasms - immunology (212) 212
drug therapy (211) 211
carcinoma, transitional cell - drug therapy (206) 206
cytokines (206) 206
skin neoplasms - therapy (200) 200
disease progression (194) 194
mice, inbred c57bl (193) 193
neoplasm transplantation (189) 189
neoplasm metastasis (188) 188
neoplasm recurrence, local (188) 188
research article (188) 188
immunity (187) 187
melanoma - immunology (186) 186
infectious diseases (185) 185
superficial bladder-cancer (184) 184
urinary bladder neoplasms - surgery (181) 181
antineoplastic agents - administration & dosage (177) 177
dendritic cells (174) 174
child (173) 173
urothelial carcinoma (173) 173
prospective studies (172) 172
t-lymphocytes - immunology (172) 172
medicine, research & experimental (171) 171
microbiology (171) 171
expression (170) 170
mycobacterium tuberculosis - immunology (170) 170
bladder neoplasms (167) 167
mitomycin-c (167) 167
bcg vaccine - pharmacology (166) 166
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4863) 4863
French (179) 179
Japanese (111) 111
German (110) 110
Spanish (63) 63
Italian (44) 44
Russian (43) 43
Polish (20) 20
Czech (18) 18
Hungarian (15) 15
Portuguese (9) 9
Chinese (7) 7
Swedish (6) 6
Hebrew (5) 5
Bulgarian (3) 3
Romanian (3) 3
Croatian (2) 2
Dutch (2) 2
Finnish (2) 2
Korean (2) 2
Turkish (2) 2
Danish (1) 1
Norwegian (1) 1
Persian (1) 1
Serbian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BJU International, ISSN 1464-4096, 08/2013, Volume 112, Issue 3, pp. 288 - 297
Journal Article
Current Opinion in Oncology, ISSN 1040-8746, 03/2017, Volume 29, Issue 3, pp. 184 - 195
PURPOSE OF REVIEWT-cell checkpoint blockade has become a dynamic immunotherapy for bladder cancer. In 2016, atezolizumab, an immune checkpoint inhibitor,... 
neoantigen | urothelial carcinoma | bladder cancer | mutational burden | immune checkpoint | combination immunotherapy | biomarker | CTLA-4 BLOCKADE | MULTICENTER | BCG | METASTATIC UROTHELIAL CARCINOMA | CISPLATIN PLUS IPILIMUMAB | OPEN-LABEL | ANTI-PD-L1 ANTIBODY | ONCOLOGY | CLINICAL ACTIVITY | EXPRESSION | AVELUMAB MSB0010718C | GENITOURINARY SYSTEM | Edited by Arif Hussain
Journal Article
Journal of Surgical Oncology, ISSN 0022-4790, 03/2014, Volume 109, Issue 4, pp. 320 - 326
Journal Article
Cancer Science, ISSN 1347-9032, 12/2015, Volume 106, Issue 12, pp. 1659 - 1668
Immune‐enhancing adjuvants usually targets antigen (Ag)‐presenting cells to tune up cellular and humoral immunity. CD141+ dendritic cells (DC) represent the... 
PolyI:C | Toll‐like receptor 2/3 | Antigen‐presenting dendritic cell (CD8α+ DC, CD141+ DC) | BCG–CWS | TICAM‐1 pathway | TICAM-1 pathway | DC, CD141 | BCG-CWS | Antigen-presenting dendritic cell (CD8α | Toll-like receptor 2/3 | DC | Cell competition | NATURAL-KILLER-CELLS | DOUBLE-STRANDED-RNA | BACILLUS-CALMETTE-GUERIN | cell death | LUNG-CANCER | CELL-WALL SKELETON | cellular senescence | tumor progression | ONCOLOGY | SUPPRESSOR-CELLS | cellular cooperation | PATTERN-RECOGNITION RECEPTORS | T-CELLS | CD8-ALPHA(+) DENDRITIC CELLS | CROSS-PRESENTATION | Cancer Vaccines - immunology | Immunotherapy - methods | Adjuvants, Immunologic - pharmacology | Animals | Toll-Like Receptor 2 - agonists | Humans | Toll-Like Receptor 3 - agonists | Antigens | Care and treatment | Dendritic cells | Analysis | Immunotherapy | Vaccines | Drug therapy | T cells | Cancer | CD8 antigen | Bladder | Lymphocytes T | Kinases | Cancer vaccines | Proteins | Hepatitis | Toll-like receptors | Bacteria | Immunity (humoral) | Natural killer cells | Immune system | Pathogens | Medical research | Cell survival | TLR7 protein | Cytokines | Peptidoglycans | Adjuvants | Inflammation | Pattern recognition | TLR3 protein | TLR9 protein | CD4 antigen | Lipoproteins | TLR1 protein | Major histocompatibility complex | TLR2 protein | Agonists | Chemokines | Apoptosis | Review | Toll‐like receptor 2
Journal Article
JOURNAL OF HEMATOLOGY & ONCOLOGY, ISSN 1756-8722, 04/2017, Volume 10, Issue 1, pp. 95 - 14
Treatment of cancer patients involves a multidisciplinary approach including surgery, radiotherapy, and chemotherapy. Traditionally, patients with metastatic... 
BLADDER-CANCER | BACILLUS-CALMETTE-GUERIN | Durvalumab | Interleukin | Ipilimumab | PROSTATE-SPECIFIC ANTIGEN | Bladder | Kidney | RENAL-CELL CARCINOMA | Pembrolizumab | Immunotherapy | PD-L1 | CTLA-4 | Sipuleucel-T | HIGH-DOSE INTERLEUKIN-2 | HEMATOLOGY | CLINICAL ACTIVITY | Checkpoint inhibitor | BCG | FREQUENT PD-L1 EXPRESSION | Genitourinary malignancy | PROSTVAC | ONCOLOGY | PHASE-I TRIAL | Nivolumab | ACTIVATED KILLER-CELLS | PD-1 | Prostate | Cancer | Atezolizumab | Adaptive Immunity | Humans | Interferon-alpha - therapeutic use | Interleukin-2 - therapeutic use | Neoplasm Proteins - immunology | Antibodies, Monoclonal - therapeutic use | Neoplasm Proteins - antagonists & inhibitors | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Clinical Trials as Topic | CTLA-4 Antigen - immunology | Immunity, Innate | B7-H1 Antigen - immunology | Cancer Vaccines - therapeutic use | B7-H1 Antigen - antagonists & inhibitors | Multicenter Studies as Topic | Antineoplastic Agents, Immunological - therapeutic use | Urogenital Neoplasms - therapy | Biomarkers | Programmed Cell Death 1 Receptor - immunology | CTLA-4 Antigen - antagonists & inhibitors | Antibodies, Monoclonal - immunology | Antigens | Cytokines | Palliation | Melanoma | Clinical trials | Cytotoxicity | Metastasis | Radiation therapy | Cancer therapies | Metastases | Side effects | Chemotherapy | Lymphocytes | Medical prognosis | Surgery | Ligands | Interferon | Prostate cancer | Cytotoxic agents | Immune system | Tumors
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 02/2016, Volume 65, Issue 2, pp. 223 - 234
Journal Article
Journal Article